Company intelligence / Profile preview

Mesh Suture

Chicago, Illinois, United Statesmeshsuture.com ↗

Ownership: Private
Development stage: Commercial

Overview

Mesh Suture has developed DURA MESH™, a novel nonabsorbable polypropylene mesh suture designed to address the problem of suture pull-through during soft tissue repair. The product combines the handling properties of a traditional suture with the force distribution and tissue incorporation benefits of a surgical mesh. Clinical registry data from hundreds of cases show lower complication rates than conventional sutures. The product received FDA clearance in September 2022 for use in soft tissue approximation including muscles, fascia, tendons, and ligaments. It is commercially available in the US/EU/UK.

Therapeutic areas: Other
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Duramesh

Commercial

Indications: Soft tissue repair, Hernia repair, Tendon repair, Wound closure

Beyond the preview

Go deeper on Mesh Suture.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesh Suture.

Explore the full profile